• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.新辅助化疗应给予符合条件的新诊断的、潜在可切除的膀胱肌层浸润性尿路上皮癌（MIBC）患者：2013年CAGMO共识声明及简化转诊流程呼吁。
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):312-8. doi: 10.5489/cuaj.1506.
2
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.加拿大肌肉浸润性膀胱癌的治疗：一项针对泌尿生殖系统肿瘤内科医生和泌尿科医生的调查。
Can Urol Assoc J. 2014 Sep;8(9-10):309-16. doi: 10.5489/cuaj.2111.
3
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.肌肉浸润性膀胱癌（MIBC）新辅助化疗与辅助化疗的比较：来自RISC数据库的分析
Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.
4
Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.可切除的肌层浸润性膀胱癌患者的新辅助化疗与辅助化疗。
Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3641-3647. doi: 10.31557/APJCP.2022.23.11.3641.
5
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.原发性和继发性肌层浸润性膀胱癌之间的基因组差异是基于顺铂为基础的新辅助化疗疗效差异的基础。
Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.
6
Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?肌肉浸润性膀胱癌的新辅助治疗和辅助治疗：我们目前的进展如何？
Arch Esp Urol. 2020 Dec;73(10):971-985.
7
The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.上尿路尿路上皮癌肌层浸润性复发的临床病理特征。
Cancer Sci. 2021 Mar;112(3):1084-1094. doi: 10.1111/cas.14782. Epub 2021 Jan 11.
8
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.美国医学肿瘤学家对肌层浸润性膀胱癌的管理研究。
Urol Oncol. 2014 Jul;32(5):637-44. doi: 10.1016/j.urolonc.2013.12.012. Epub 2014 May 16.
9
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.原发性与继发性肌层浸润性膀胱癌诊断时对新辅助化疗反应的影响
Eur Urol Open Sci. 2022 May 28;41:74-80. doi: 10.1016/j.euros.2022.05.001. eCollection 2022 Jul.
10
Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.当代肌层浸润性膀胱癌女性中妇科器官受累的比例：新辅助化疗后行根治性膀胱切除术的女性回顾性研究。
J Urol. 2021 Sep;206(3):577-585. doi: 10.1097/JU.0000000000001784. Epub 2021 Apr 19.

引用本文的文献

1
Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients.膀胱癌患者行尿液改道后肾功能改善以符合顺铂治疗条件。
Bladder (San Franc). 2025 Mar 3;12(1):e21200027. doi: 10.14440/bladder.2024.0034. eCollection 2025.
2
2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.2025年加拿大泌尿外科学会专家报告：肌层浸润性膀胱癌
Can Urol Assoc J. 2025 Jan;19(1):E1-E16. doi: 10.5489/cuaj.9096.
3
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.新辅助化疗对比单纯根治性膀胱切除术改善肌层浸润性膀胱癌患者总生存的荟萃分析。
BMC Urol. 2020 Oct 14;20(1):158. doi: 10.1186/s12894-020-00733-z.
4
Canadian Urological Association guideline: Muscle-invasive bladder cancer.加拿大泌尿外科协会指南：肌层浸润性膀胱癌
Can Urol Assoc J. 2019 Aug;13(8):230-238. doi: 10.5489/cuaj.5902.
5
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49 parallel.肌肉浸润性膀胱癌的新辅助化疗：在49个平行研究中未得到充分利用。
Can Urol Assoc J. 2019 Feb;13(2):29-31. doi: 10.5489/cuaj.5827.
6
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.改善患者就医流程与医疗质量：加拿大膀胱癌-加拿大泌尿外科协会-加拿大泌尿肿瘤学组（BCC-CUA-CUOG）第二届膀胱癌医疗质量共识会议总结
Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19.
7
Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers.膀胱癌围手术期化疗：对医疗服务提供者的调查以确定障碍和促进因素
Bladder Cancer. 2018 Jan 20;4(1):49-65. doi: 10.3233/BLC-170148.
8
Perioperative chemotherapy for bladder cancer: A qualitative study of physician knowledge, attitudes, and behaviour.膀胱癌围手术期化疗：医生知识、态度及行为的定性研究
Can Urol Assoc J. 2018 Apr;12(4):E182-E190. doi: 10.5489/cuaj.4791. Epub 2017 Dec 22.
9
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.加拿大膀胱癌医疗质量改善建议：一份由加拿大膀胱癌协会（BCC）、加拿大泌尿外科肿瘤学组（CUOG）和加拿大泌尿外科协会（CUA）于2015年12月审核并认可的共识文件。
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8.
10
Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.肌层浸润性膀胱癌的围手术期化疗：弥合证据与实践之间的差距
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):31-2. doi: 10.5489/cuaj.3600.

本文引用的文献

1
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.加拿大肌肉浸润性膀胱癌的治疗：一项针对泌尿生殖系统肿瘤内科医生和泌尿科医生的调查。
Can Urol Assoc J. 2014 Sep;8(9-10):309-16. doi: 10.5489/cuaj.2111.
2
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.新辅助顺铂和吉西他滨化疗治疗肌层浸润性膀胱癌的临床结局的汇总分析。
J Urol. 2013 May;189(5):1682-6. doi: 10.1016/j.juro.2012.10.120. Epub 2012 Nov 1.
3
Urothelial carcinoma of the bladder and the upper tract: disparate twins.膀胱和上尿路尿路上皮癌：迥异的双生子。
J Urol. 2013 Apr;189(4):1214-21. doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.
4
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.根治性膀胱切除术时尿路上皮癌的升级：与升级相关的因素及其对结果的影响。
BJU Int. 2012 Sep;110(6):804-11. doi: 10.1111/j.1464-410X.2012.10939.x. Epub 2012 Feb 9.
5
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.病理降期是新辅助化疗和根治性膀胱切除术治疗肌层浸润性尿路上皮膀胱癌后疗效和生存率提高的替代标志物。
Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.
6
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.新辅助化疗后肌层浸润性膀胱癌根治性切除术的高效实施：多学科方法。
Cancer. 2012 Jan 1;118(1):44-53. doi: 10.1002/cncr.26240. Epub 2011 May 19.
7
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.评估新辅助顺铂、甲氨蝶呤和长春碱化疗治疗肌层浸润性膀胱癌的国际 III 期临床试验：BA0630894 试验的长期结果。
J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.
8
Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience.2287 例膀胱癌患者接受根治性膀胱切除术治疗的当代结果：加拿大多中心经验。
BJU Int. 2011 Aug;108(4):539-45. doi: 10.1111/j.1464-410X.2010.09912.x. Epub 2010 Dec 16.
9
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.肌层浸润性膀胱癌患者围手术期顺铂为基础化疗的应用现状。
Cancer. 2011 Jan 15;117(2):276-82. doi: 10.1002/cncr.25429. Epub 2010 Sep 9.
10
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy.根治性膀胱切除术治疗临床 T2 尿路上皮癌的临床病理结局：支持新辅助化疗应用的进一步证据。
BJU Int. 2011 Jan;107(1):58-62. doi: 10.1111/j.1464-410X.2010.09442.x.

新辅助化疗应给予符合条件的新诊断的、潜在可切除的膀胱肌层浸润性尿路上皮癌（MIBC）患者：2013年CAGMO共识声明及简化转诊流程呼吁。

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

作者信息

Seah Jo-An, Blais Normand, North Scott, Rahim Yasmin, Ruether Dean, Black Peter C, Zlotta Alexandre R, Wood Lori, Sridhar Srikala S

机构信息

Princess Margaret Hospital, Toronto, ON;

出版信息

Can Urol Assoc J. 2013 Sep-Oct;7(9-10):312-8. doi: 10.5489/cuaj.1506.

DOI:10.5489/cuaj.1506
PMID:24319508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3854467/
Abstract

Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

摘要

新辅助化疗（NC）可提高可切除的膀胱肌层浸润性尿路上皮癌（MIBC）患者的总生存率。然而，加拿大新辅助化疗的应用率低得令人失望。在进行详细的文献综述并咨询泌尿肿瘤学专家后，加拿大泌尿生殖医学肿瘤学家协会（CAGMO）制定了关于在MIBC中使用新辅助化疗的共识声明。我们的主要目标是提高加拿大MIBC患者新辅助化疗的应用率，并改善患者的治疗效果。